Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are Peroxisome proliferator-activated receptor gamma (PPARγ) agonists initially used to control blood glucose levels in type 2 diabetes but have shown complex effects in AMD. Here, PPARG is linked to type 2 diabetes mellitus.